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Abstract
Background: The aim was to determine predictors of hospital and 1-year mortality in patients with intensive care
unit (ICU)-treated refractory status epilepticus (RSE) in a population-based study.
Methods: This was a retrospective study of the Finnish Intensive Care Consortium (FICC) database of adult patients
(16 years of age or older) with ICU-treated RSE in Finland during a 3-year period (2010–2012). The database consists
of admissions to all 20 Finnish hospitals treating RSE in the ICU. All five university hospitals and 11 out of 15 central
hospitals participated in the present study. The total adult referral population in the study hospitals was 3.92
million, representing 91% of the adult population of Finland. Patients whose condition had a post-anoxic
aetiological basis were excluded.
Results: We identified 395 patients with ICU-treated RSE, corresponding to an annual incidence of 3.4/100,000
(95% confidence interval (CI) 3.04–3.71). Hospital mortality was 7.4% (95% CI 0–16.9%), and 1-year mortality was 25.
4% (95% CI 21.2–29.8%). Mortality at hospital discharge was associated with severity of organ dysfunction. Mortality
at 1 year was associated with older age (adjusted odds ratio (aOR) 1.033, 95% CI 1.104–1.051, p = 0.001), sequential
organ failure assessment (SOFA) score (aOR 1.156, CI 1.051–1.271, p = 0.003), super-refractory status epilepticus (SRSE)
(aOR 2.215, 95% CI 1.20–3.84, p = 0.010) and dependence in activities of daily living (ADL) (aOR 2.553, 95% CI
1.537–4.243, p < 0.0001).
Conclusions: Despite low hospital mortality, 25% of ICU-treated RSE patients die within a year. Super-refractoriness,
dependence in ADL functions, severity of organ dysfunction at ICU admission and older age predict long-term
mortality.
Trial registration: Retrospective registry study; no interventions on human participants.
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Background
Status epilepticus (SE) is a neurological emergency that
may cause death and marked neurological deficiency. SE
is called refractory status epilepticus (RSE) if the first-
line and second-line medication does not terminate the
seizure, and it is referred to super-refractory SE (SRSE)
if it continues over 24 h after the onset of the first an-
aesthesia [1]. Less than 50% of patients with SE have had
previous seizures or epilepsy. There are several other ae-
tiologies, but the cause is usually an underlying acute
neurological disease, systemic disorder or condition with
a remote aetiological basis after previous central nervous
system injury [2, 3].
Data on the long-term outcomes of SE are scarce, par-
ticularly in the cases of RSE and SRSE, and they are
based on small patient cohorts [4]. Age, aetiology of dis-
ease, type of seizure at onset, treatment delay, level of
consciousness at presentation, use of electroencephalog-
raphy (EEG) and delay in admission to the intensive care
unit (ICU) are reported to affect outcomes [4–7]. In-
hospital seizures seem to have worse outcomes than
those starting outside the hospital setting [7, 8]. More-
over, there are both national and international guidelines
and algorithms for better treatment of SE [2, 9–13];
however, the outcomes remain poor: Short-term mor-
tality in adult SE and RSE vary in the range of 19–
39% [6, 14], while longer-term mortality is in the
range of 35–43% [4, 15]. Long-term mortality in SRSE
is twofold higher than in RSE alone [16]. The mortal-
ity of SE is correlated with seizure duration, rapid
identification of SE and aetiology of disease [1].
Our study group has recently reported on the inci-
dence of SRSE and the mortality rates in patients with
SRSE from this same patient cohort [16]. The aim of the
present study was to determine predictors of hospital
and 1-year mortality in ICU-treated patients with RSE,
including patients evolving to SRSE, in a nationwide
population-based study.
Methods
Data source
The Finnish Intensive Care Consortium (FICC) is a
body responsible for a national ICU benchmarking
programme and database in Finland. All 20 major
central and university hospitals, providing all second-
ary and tertiary care, ICUs and neurological services
for their referral population in Finland, joined the
consortium by 2007. The FICC database collects data
from every ICU admission from all general adult
ICUs in all 20 Finnish hospital districts.
Information on clinical characteristics, severity of ill-
ness and outcomes is collected in the database; this is
validated by each participating ICU before submission to
the central database [17]. All 5 university hospitals and
11 out of 15 central hospitals participated in the present
study. Both ICU physicians and neurologists participate
in the diagnostics and patient care in these ICUs. We
used the FICC database and medical records to identify
adult patients (age 16 years or over) with RSE treated
with general anaesthesia in the ICU) in a population-
based cohort in Finland during the 3-year period of
2010–2012. This study received FICC Board approval to
access the database, while the authorities responsible for
specific hospital districts authorised the use of medical
records data.
Patients
We included consecutive adult patients (age 16 years
or older) with RSE treated with general anaesthesia.
To identify patients treated in an ICU for seizure dis-
orders, we first searched the FICC database for pa-
tients who had been classified under the acute
physiology and chronic health evaluation (APACHE)
II diagnostic group “seizure”’ [18] or for whom one of
the ICD-10 codes for epilepsy, SE or convulsions
(G40.X, G41.X or R56.8) had been documented. We
only included patients who had been treated in the
ICU for at least 48 h, which we estimated to be the
minimum duration of treatment and weaning period
for patients with RSE treated with general anaesthesia.
Intensive care unit physicians at each participating
hospital re-evaluated the patients’ medical records to
identify patients with RSE, that is, patients who had
prolonged seizures that did not improve with first-
line and second-line treatment with antiepileptic
drugs (AEDs) and were treated with general anaesthe-
sia in the ICU. Patients with post anoxic aetiologies
were excluded. Altogether 395 incidents of RSE ful-
filled the final inclusion criteria (Fig. 1).
Clinical factors
The simplified acute physiology score II (SAPS II) [19]
and sequential organ failure assessment (SOFA) score
[20] for the first 24 h in the ICU, describing the sever-
ity of organ failure and illness, were collected from the
FICC database. Independence in activities of daily
living (ADL) was coded as independent or non-
independent (with supervision, direction or personal
assistance) as a measure of each patient’s pre-morbid
functional capacity. The Glasgow coma scale (GCS)
for describing the impairment of consciousness was
assessed at the time of ICU admission before any
sedative medication was administered. Data on access
to diagnostic EEG and continuous EEG monitoring
during the ICU stay and data on the intravenous an-
aesthetics given were obtained from medical records
by local intensive care physicians.
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Statistical analysis
Statistical analyses were conducted using SPSS soft-
ware version 22 (IBM Corp, Armonk, NY, USA). We
calculated the population incidence for RSE and 95%
confidence intervals (CIs) for a single incidence rate.
The chi-square test was used to compare the categor-
ical variables, and nonparametric tests (Mann–Whitney
U for test for the median) were used with continuous
variables. Variables that were significant in univariate
analyses were included in binary logistic multivariate
regression analysis with the backward likelihood-ratio
technique and significance variance exclusion set at
0.10.
Results
Patients and incidence
We identified 395 patients treated for RSE in the ICU
during a 3-year period. The adult population of the par-
ticipating 16 hospital districts is 3.92 million, represent-
ing 91% of the total Finnish adult population. The
annual incidence of ICU-treated RSE was 3.4/100,000
(95% CI 3.04–3.71). Of the 395 patients, 264 (66.8%)
were treated in university hospitals. The median age of
the patients was 58 years (interquartile range (IQR) 46–
67], and 245 (62.3%) of the patients were male. The me-
dian length of the ICU stay was 5.0 days (IQR 3.5–8),
and the overall median hospital stay was 13 days (IQR
8–21). Altogether, 112 (28.2%) patients in the cohort
needed help in their ADL functions before hospital
treatment. Demographics and data are shown in Table 1.
Diagnostics and treatment
Diagnostic EEG data were available for 186 patients
(47.1%) and continuous EEG monitoring during anaes-
thesia was available for 313 (80.1%) of the RSE patients.
Altogether, 39 patients (9.9%) had neither diagnostic nor
continuous EEG monitoring. Propofol was given for 12–
24 h as the first intravenous anaesthetic (IVA) in 373 of
the patients (94.4%), whereas thiopental was adminis-
tered for 12–24 h in 17 patients (4.3%). SRSE was identi-
fied in 87 patients (22.0%).
Mortality
Hospital mortality
The ICU mortality was 4/395 (1%, 95% CI 0–10.8%),
and total hospital mortality was 29/395 (7.4%, 95% CI
0–16.9%). In multivariate regression analysis, the SOFA
score was an independent predictor of hospital mortal-
ity. Neither age nor premorbid ADL stage predicted hos-
pital mortality (Fig. 2, Table 2).
One-year mortality
A total of 366 (92.7%) patients were discharged from
hospital. Only 23.8% of the patients were discharged to
home. Most patients (47.4%) were discharged to primary
healthcare wards and 21.0% to specialist care facilities.
Ninety-nine patients (25.4%, 95% CI 21.2–29.8) died
within 12 months of ICU admission. The discharge des-
tination was highly predictive of outcomes at 12 months:
only 5.4% of patients discharged to their home died, but
mortality was 18.3% among those discharged to special-
ist care hospitals and 28.1% for patients discharged to
primary care wards (p = 0.001). Mortality at 1 year was
associated with older age, SRSE, severity of organ failure
and lower premorbid capacity of ADL functions
(Table 2). Both increasing age and poor premorbid func-
tional performance were strong predictors of increased
1-year mortality (Fig. 2). Level of consciousness was
measured by the GCS at presentation (median score 5
(IQR 4–10)), and there was no significant association
with hospital mortality (p = 0.14) or 1-year mortality
(p = 0.11).
Discussion
Our study represents the first population-based, nation-
wide cohort showing the incidence and long-term mor-
tality in ICU-treated and anaesthesia-treated RSE and
SRSE. The incidence of RSE in our population-based co-
hort was 3.4/100,000/year, and the incidence SRSE in
our cohort was 0.7/100,000/year [16], constituting 22%
of the patients with RSE. Depending on the definition of
RSE that was used, 4–26% of patients with RSE have
previously been reported to develop SRSE [21]. According
Fig. 1 Data collection flowchart. The Finnish Intensive Care Consortium (FICC) database had 52,394 ICU admissions in 2010–2012, and 395
patients met the study criteria of intensive care unit (ICU) general anaesthesia-treated refractory status epilepticus (RSE). APACHE acute physiology
and chronic health evaluation
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to Delaj et al. [21], if all patients with RSE are included,
the frequency of SRSE is 4%, and if only intubated patients
with RSE are included (as in our study), the frequency is
42%.
The rates of ICU mortality (1%) and hospital mor-
tality (7%) in our study are comparable with recently
reported rates of ICU mortality (2%) and hospital
mortality (5%) in Australia and New Zealand [22], al-
though this study included all prolonged seizures and
not only RSE. The 1-year mortality rate (25%) in RSE
in the present population-based study is relatively low
compared to those reported in earlier studies, in
which long-term mortality was in the rage of 26–62%
(time variance of 1–12 months) [4, 23–26]. Conse-
quently, the outcome in patients with RSE deterio-
rates after the period of stay in the ICU and the first
weeks of hospitalisation, and one fourth of these pa-
tients die within a year.
Fig. 2 Hospital and one-year mortality by age quartiles and premorbid functional status. ADLs activities of daily living
Table 1 Demographics and clinical characteristics by hospital and one-year mortality
By hospital outcome n = 394 By one-year outcome n = 390
All
n = 395
Survivors
n = 365
Non-survivors
n = 29
P value Survivors
n = 291
Non-survivors
n = 99
P value
Age, years, median (IQR) 58 (46–67) 58 (43–67) 62 (54–73) 0.033 55 (41.5–65) 62 (53–72.5) <0.001
Male, n (%) 245 (62.3%) 229 (62.7%) 16 (55.2%) 0.41 185 (63.6%) 57 (57.6%) 0.25
Needing help in ADL, n (%) 112 (28.3%) 103 (28.2%) 9 (31.0%) 0.72 67 (23.0%) 44 (44.4%) 0.000037 < 0.001
SAPS II, median (IQR) 47 (36.5–57) 47 (36–57) 56 (47–60) 0.003 45 (35–55) 52 (43–61) <0.001
SOFA, median (IQR) 8 (6–10) 8 (6–10) 10 (8–11) 0.005 8 (6–10) 9 (7–11) 0.003
SOFA score without CNS points, median (IQR) 5 (4–6) 5 (4–6) 6 (4.5–9) 0.005 5 (4–6) 5 (4–7) 0.013
GCS, median (IQR) 5 (4–10) 6 (4–10) 5 (3–7.5) 0.14 6 (4–10) 5 (3–8) 0.11
GCS <6, n (%) 195 (49.3%) 178 (48.8%) 17 (58.6%) 0.25 149 (51.2%) 42 (42.4%) 0.11
SRSE, n (%) 87 (22.0%) 78 (21.4%) 9 (31.0%) 0.15 54 (18.4%) 30 (30.3%) 0.011
Admission from ward, n (%) 71 (18.0%) 63 (17.3%) 8 (26.7%) 0.16 45 (15.5%) 25 (25.3%) 0.029
LOS ICU, median (IQR) 5.0 (3.5–8.0) 5.0 (3.5–7.8) 6.5 (4.1–10) 0.048 4.9 (3.2–7.8) 5.8 (3.9–9.1) 0.054
LOS hospital, median (IQR) 13 (8–21) 13 (8–22) 12 (8–19) 0.77 13 (8–21) 14 (9–22) 0.27
Hospital discharge 0.001
Home, n (%) 94 (23.8%) 88 (30.2%) 5 (5.0%)
Specialist care hospital/ward, n (%) 86 (21.0%) 67 (23.0%) 15 (11.3%)
Primary care hospital/ward, n (%) 185 (47.4%) 133 (45.7%) 52 (28.1%)
Died in hospital, n (%) 29 (7.4%)
ADL activities of daily living, SAPS II simplified acute physiology score II, SOFA sequential organ failure assessment, GCS Glasgow coma scale, SRSE super-refractory
status epilepticus, LOS length of stay, ICU intensive care unit
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We found that older age, SRSE, premorbid depend-
ence in ADL and severity of organ dysfunction are asso-
ciated with unfavourable long-term outcomes. Our data
show that mortality doubles within 12 months if the pa-
tient needs help in ADL functions before the RSE inci-
dent and ICU admission. SOFA scores defining patient
organ dysfunction and comorbidities are associated with
poor long-term outcomes. Age and comorbidities have
also been reported as measures of poor outcome in
other studies of RSE [27–30]. The question remains as
to whether it is the RSE, the aetiology of RSE, the
patient’s pre-existing characteristics or the ICU treat-
ment that explains the poor long-term outcome. This
phenomenon is also seen in other ICU cohorts and stud-
ies of other diseases [31–33]. Age, comorbidities and
frailty have major effects on the long-term outcomes of
intensive care in general. In this study, level of con-
sciousness measured by GCS at presentation to ICU did
not predict mortality. This finding is in accordance with
earlier studies by Sutter et al. [5, 34] in patients with
RSE after excluding patients with hypoxic–ischaemic
encephalopathy, as we have done in this cohort.
Consistency with the Finnish Current Care guideline
was good in the choice of the first intravenous anaes-
thetic (IVA): propofol, the suggested drug, was used in
94% of patients [9]. Compliance with the guideline in ac-
cess to diagnostic EEG and continuous EEG monitoring
during anaesthesia was lower. Diagnostic EEG evaluation
was used in less than half of the patients (47%), and
continuous EEG monitoring was employed in 80% of pa-
tients. However, only 10% of the patients were treated
without any EEG evaluation. RSE diagnostics should in-
clude EEG along with clinical judgement to differentiate
between seizure activity, post seizure and medication-
derived conditions and non-epileptic seizures (NES).
Patients can also be attended in the emergency depart-
ment (ED) after having been sedated and intubated by
paramedics and emergency doctors; therefore, evaluation
of ongoing seizure activity and clinical presentation is
necessary. Monitoring the depth of the coma and sup-
pression of seizure activity, and secondarily, burst sup-
pression (BS), is essential when titrating the depth of
anaesthesia [9, 10].
Our study demonstrated that access to diagnostic EEG
and continuous EEG monitoring during on-call hours is
still not perfectly organised nationwide. This problem
seems to be international; according to a recent article
only 33% of the hospital trusts treating RSE in the UK
had access to continuous EEG [35]. In our cohort, pa-
tients with no EEG data (10% of patients) were diag-
nosed as having RSE patients based on clinical
judgement only. Unfortunately we have no data on AED
management during the withdrawal of anaesthetics in
the present study. This would be important because fail-
ure of the first anaesthesia and the occurence of SRSE
may unnecessarily occur after inadequate use of back-
ground AEDs and not due to the refractoriness of the SE
itself. Concomitant AED therapy should be started to
Table 2 Predictors of hospital and one-year mortality
Predictor Univariate analysis Multivariate analysis
OR 95% CI P value Adjusted OR 95% CI P value
Hospital mortality
Age 1.030 1.002–1.059 0.039 NS
Male gender 0.73 0.34–1.56 0.41 NS
Non-independence in ADL 1.16 0.51–2.66 0.72 NS
SOFA 1.25 1.09–1.44 0.002 1.22 1.06–1.41 0.007
GCS 0.93 0.83–1.04 0.18 NS
SRSE 1.83 0.79–4.24 0.16 2.04 0.86–4.84 0.104 NS
Admission from ward 1.83 0.77–4.31 0.17 NS
One-year mortality
Age 1.04 1.02–1.06 <0.001 1.03 1.01–1.05 <0.001
Male gender 0.76 0.48–1.22 0.25 NS
Non-independence ADL 2.73 1.68–4.44 <0.001 2.55 1.46–4.13 0.001
SOFA 1.16 1.07–1.27 0.001 1.17 1.06–1.30 0.002
GCS 0.95 0.89–1.01 0.084
SRSE 1.95 1.16–3.29 0.012 2.215 1.20–3.84 0.010
Admission from ward 1.84 1.06–3.20 0.031 1.73 0.94–3.2 0.08 NS
OR odds ratio, CI confidence interval, ADL activities of daily living, SOFA sequential organ failure assessment, GCS Glasgow coma scale, SRSE super-refractory status
epilepticus, NS not significant. P values in italics are statistically significant
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prevent the recurrence of RSE, and it should be contin-
ued parallel to the acute emergency treatment to ensure
adequate levels of AED medication both with intravenous
preparations and via the nasogastric tube or percutaneus
endoscopic gastrostomy if necessary. Patients with pre-
existing epilepsy should have their previous antiepileptic
medications continued with optimised doses [10].
ICU admission from a ward as compared to admission
from the ED or other monitoring units was associated
with 1-year mortality in univariate analysis. However, in
our study there was no independent effect in multivari-
ate analysis when adjusting for other risk factors. In
some earlier studies hospitalised patients had RSE of
more severe aetiology: focal brain abnormalities (stroke,
tumour or trauma) or systemic metabolic disturbances
had a worse outcome associated with the aetiology of
the condition [8, 36]. In addition, as seizure duration
over 1 h and especially over 24 h is associated with
greater mortality in patients with RSE, a longer delay in
treatment may be a factor in the poorer prognosis for
patients with in-hospital RSE. Seizures are better recog-
nised in the ED and monitoring units than in an in-
patient ward setting [15, 37].
Study limitations
A retrospective registry study has limitations: this na-
tionwide study lacked information on the aetiology of
RSE and long-term neurological outcomes apart from
mortality. In addition, we did not have data on patients
who may have had RSE but were treated outside of ICUs
because of the presumed futility of intensive care. How-
ever, this is a large population-based study of 395 pa-
tients with ICU-treated RSE. The referral population of
the participating hospitals represents over 90% of the
Finnish population, and all major hospital districts and
university hospitals with their catchment areas were in-
cluded. We consider this study population highly repre-
sentative of all patients with ICU-treated RSE in Finland.
Conclusions
We conclude that ICU-treated RSE is a neurological
emergency with a substantial 1-year mortality rate. Des-
pite low mortality rates in the ICU and in hospital, 25%
of the patients in our study died within a year. Older
age, SRSE, premorbid non-independence in ADL func-
tions and severity of organ failure predicted mortality at
1 year. Early effective treatment and preventing SE from
developing into RSE would probably represent the best
treatment actions to reduce mortality in RSE. Intensive
care and general anaesthesia are the mainstays of treat-
ment for RSE. Elderly or otherwise frail patients with
impaired functional performance should be identified
early and evaluated thoroughly individually; such patients
should possibly be treated with a less aggressive method.
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